Verastem, Inc. clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.

1. Notable

   VS-7375 · KRAS G12D-Mutated Solid Tumors

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 295 → 616 participants; Interventions modified

   Verastem, Inc.·Phase 1/2· NCT07020221· Registry history of NCT07020221 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.